Search

Your search keyword '"Bertolini, Federica"' showing total 166 results
Start Over Author "Bertolini, Federica" Search Limiters Full Text
166 results on '"Bertolini, Federica"'

1. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)

Author

Celio, Luigi, Cortinovis, Diego, Cogoni, Alessio Aligi, Cavanna, Luigi, Martelli, Olga, Carnio, Simona, Collovà, Elena, Bertolini, Federica, Petrelli, Fausto, Cassano, Alessandra, Chiari, Rita, Zanelli, Francesca, Pisconti, Salvatore, Vittimberga, Isabella, Letizia, Antonietta, Misino, Andrea, Gernone, Angela, Bonizzoni, Erminio, Pilotto, Sara, De Placido, Sabino, and Bria, Emilio

Published
2023
Full Text
View/download PDF

2. A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study

Author

Bogani, Giorgio, Cinquini, Michela, Signorelli, Diego, Pizzutilo, Elio G., Romanò, Rebecca, Bersanelli, Melissa, Raggi, Daniele, Alfieri, Salvatore, Buti, Sebastiano, Bertolini, Federica, Bonomo, Pierluigi, Marandino, Laura, Rizzo, Mimma, Monteforte, Marta, Aiello, Marco, Tralongo, Antonio C., Torri, Valter, Di Donato, Violante, and Giannatempo, Patrizia

Published
2023
Full Text
View/download PDF

3. Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience

Author

Andrikou, Kalliopi, primary, Ulivi, Paola, additional, Petracci, Elisabetta, additional, Azzali, Irene, additional, Bertolini, Federica, additional, Alberti, Giulia, additional, Bettelli, Stefania, additional, Calistri, Daniele, additional, Chiadini, Elisa, additional, Capelli, Laura, additional, Cravero, Paola, additional, Guaitoli, Giorgia, additional, Zanelli, Francesca, additional, Burgio, Marco Angelo, additional, Pagano, Maria, additional, Verlicchi, Alberto, additional, Martinelli, Enrica, additional, Di Emidio, Katia, additional, Dominici, Massimo, additional, Pinto, Carmine, additional, and Delmonte, Angelo, additional

Published
2024
Full Text
View/download PDF

4. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

Author

Celio, Luigi, Cortinovis, Diego, Cogoni, Alessio Aligi, Cavanna, Luigi, Martelli, Olga, Carnio, Simona, Collovà, Elena, Bertolini, Federica, Petrelli, Fausto, Cassano, Alessandra, Chiari, Rita, Zanelli, Francesca, Pisconti, Salvatore, Vittimberga, Isabella, Letizia, Antonietta, Misino, Andrea, Gernone, Angela, Bonizzoni, Erminio, Pilotto, Sara, De Placido, Sabino, and Bria, Emilio

Published
2022
Full Text
View/download PDF

5. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Author

Cortellini, Alessio, Giusti, Raffaele, Filetti, Marco, Citarella, Fabrizio, Adamo, Vincenzo, Santini, Daniele, Buti, Sebastiano, Nigro, Olga, Cantini, Luca, Di Maio, Massimo, Aerts, Joachim G. J. V., Bria, Emilio, Bertolini, Federica, Ferrara, Miriam Grazia, Ghidini, Michele, Grossi, Francesco, Guida, Annalisa, Berardi, Rossana, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Antonuzzo, Lorenzo, Gelibter, Alain, Marchetti, Paolo, Chiari, Rita, Macerelli, Marianna, Rastelli, Francesca, Della Gravara, Luigi, Gori, Stefania, Tuzi, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Pecci, Federica, Zoratto, Federica, Ricciardi, Serena, Migliorino, Maria Rita, Passiglia, Francesco, Metro, Giulio, Spinelli, Gian Paolo, Banna, Giuseppe L., Friedlaender, Alex, Addeo, Alfredo, Ficorella, Corrado, Porzio, Giampiero, Tiseo, Marcello, Russano, Marco, Russo, Alessandro, and Pinato, David James

Published
2022
Full Text
View/download PDF

6. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, Tiseo, Marcello, Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Abstract

Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27−85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1–17.9), median OS was 16.1 months (95% CI, 14.4–18.8) and PFS was 9.9 months (95% CI, 8.8–11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6–17.1). ORR was 43.4% (95% CI, 40.4–46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.

Published
2024

11. Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature

Author

Bruni, Alessio, primary, Bertolini, Federica, additional, D’Angelo, Elisa, additional, Guaitoli, Giorgia, additional, Imbrescia, Jessica, additional, Cappelli, Anna, additional, Guidi, Gabriele, additional, Stefani, Alessandro, additional, Dominici, Massimo, additional, and Lohr, Frank, additional

Published
2023
Full Text
View/download PDF

12. Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T

Author

Guaitoli, Giorgia, primary, Neri, Giovanni, additional, Cabitza, Eleonora, additional, Natalizio, Salvatore, additional, Mastrodomenico, Luciana, additional, Talerico, Sabrina, additional, Trudu, Lucia, additional, Lauro, Chiara, additional, Chiavelli, Chiara, additional, Baschieri, Maria Cristina, additional, Bruni, Alessio, additional, Dominici, Massimo, additional, and Bertolini, Federica, additional

Published
2022
Full Text
View/download PDF

13. Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres

Author

Cameli, Paolo, primary, Faverio, Paola, additional, Ferrari, Katia, additional, Bonti, Viola, additional, Marsili, Stefania, additional, Mazzei, Maria Antonietta, additional, Mazzoni, Francesca, additional, Bartolucci, Maurizio, additional, Scotti, Vieri, additional, Bertolini, Federica, additional, Barbieri, Fausto, additional, Baldessari, Cinzia, additional, Veronese, Chiara, additional, Boffi, Roberto, additional, Brighenti, Matteo, additional, Cortinovis, Diego, additional, Dominici, Massimo, additional, Pesci, Alberto, additional, Bargagli, Elena, additional, and Luppi, Fabrizio, additional

Published
2022
Full Text
View/download PDF

14. Adding Concomitant Chemotherapy to Postoperative Radiotherapy in Oral Cavity Carcinoma with Minor Risk Factors: Systematic Review of the Literature and Meta-Analysis

Author

Di Rito, Alessia, primary, Fiorica, Francesco, additional, Carbonara, Roberta, additional, Di Pressa, Francesca, additional, Bertolini, Federica, additional, Mannavola, Francesco, additional, Lohr, Frank, additional, Sardaro, Angela, additional, and D’Angelo, Elisa, additional

Published
2022
Full Text
View/download PDF

15. Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O.

Author

Miccichè, Francesco, primary, Chiloiro, Giuditta, additional, Longo, Silvia, additional, Autorino, Rosa, additional, Massaccesi, Mariangela, additional, Lenkowicz, Jacopo, additional, Bonomo, Pierluigi, additional, Desideri, Isacco, additional, Belgioia, Liliana, additional, Bacigalupo, Almalina, additional, D’Angelo, Elisa, additional, Bertolini, Federica, additional, Merlotti, Anna, additional, Denaro, Nerina, additional, Franco, Pierfrancesco, additional, Bussu, Francesco, additional, Paludetti, Gaetano, additional, Ricardi, Umberto, additional, and Valentini, Vincenzo, additional

Published
2022
Full Text
View/download PDF

16. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

Author

Banna, Giuseppe L., Tiseo, Marcello, Cortinovis, Diego L., Facchinetti, Francesco, Aerts, Joachim G.J.V., Baldessari, Cinzia, Giusti, Raffaele, Bria, Emilio, Grossi, Francesco, Berardi, Rossana, Morabito, Alessandro, Catino, Annamaria, Genova, Carlo, Mazzoni, Francesca, Gelibter, Alain, Rastelli, Francesca, Macerelli, Marianna, Chiari, Rita, Gori, Stefania, Mansueto, Giovanni, Citarella, Fabrizio, Cantini, Luca, Rijavec, Erika, Bertolini, Federica, Cappuzzo, Federico, De Toma, Alessandro, Friedlaender, Alex, Metro, Giulio, Pensieri, Maria Vittoria, Porzio, Giampiero, Ficorella, Corrado, Pinato, David J., Cortellini, Alessio, Addeo, Alfredo, Banna, Giuseppe L., Tiseo, Marcello, Cortinovis, Diego L., Facchinetti, Francesco, Aerts, Joachim G.J.V., Baldessari, Cinzia, Giusti, Raffaele, Bria, Emilio, Grossi, Francesco, Berardi, Rossana, Morabito, Alessandro, Catino, Annamaria, Genova, Carlo, Mazzoni, Francesca, Gelibter, Alain, Rastelli, Francesca, Macerelli, Marianna, Chiari, Rita, Gori, Stefania, Mansueto, Giovanni, Citarella, Fabrizio, Cantini, Luca, Rijavec, Erika, Bertolini, Federica, Cappuzzo, Federico, De Toma, Alessandro, Friedlaender, Alex, Metro, Giulio, Pensieri, Maria Vittoria, Porzio, Giampiero, Ficorella, Corrado, Pinato, David J., Cortellini, Alessio, and Addeo, Alfredo

Abstract

Background: Patients with programmed cell death-ligand 1 (PD-L1) ≥50% metastatic non-small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first-line immunotherapy have heterogeneous clinical assessment and outcomes. Methods: To explore the role of immune-inflammatory surrogates by the validated lung immuno-oncology prognostic score (LIPS) score, including the neutrophil-to-lymphocyte ratio (NLR) and the pretreatment use of steroids, alongside other prognostic variables. A retrospective analysis of 128 patients with PS2 and PD-L1 ≥50% mNSCLC treated between April 2018 and September 2019 with first-line pembrolizumab in a real-world setting was performed. Results: With a median follow-up of 15.3 months, the 1-year overall survival (OS) and median progression-free survival (PFS) were 32.3% (95% CI: 30.9–33.9) and 3.3 months (95% CI: 1.8–4.7), respectively. The NLR, lactate dehydrogenase (LDH) and pretreatment steroids results were the only significant prognostic factors on the univariate analysis and independent prognostic factors by the multivariate analysis on both OS and PFS. The LIPS score, including the NLR and pretreatment steroids, identified 29 (23%) favourable-risk patients, with 0 factors, 1-year OS of 67.6% and median PFS of 8.2 months; 57 (45%) intermediate-risk patients, with 1 factor, 1-year OS 32.1% and median PFS 2.7 months; 42 (33%) poor-risk patients, with both factors, 1-year OS of 10.7% and median PFS of 1.2 months. Conclusions: The assessment of pre-existing imbalance of the host immune response by combined blood and clinical immune-inflammatory markers may represent a way to unravel the heterogeneous outcome and assessment of patients with mNSCLC and poor PS in the immune-oncology setting.

Published
2022

17. Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups

Author

Perrone, Fabiana, primary, Mazzaschi, Giulia, additional, Minari, Roberta, additional, Verzè, Michela, additional, Azzoni, Cinzia, additional, Bottarelli, Lorena, additional, Nizzoli, Rita, additional, Pluchino, Monica, additional, Altimari, Annalisa, additional, Gruppioni, Elisa, additional, Sperandi, Francesca, additional, Andrini, Elisa, additional, Guaitoli, Giorgia, additional, Bertolini, Federica, additional, Barbieri, Fausto, additional, Bettelli, Stefania, additional, Longo, Lucia, additional, Pagano, Maria, additional, Bonelli, Candida, additional, Tagliavini, Elena, additional, Nicoli, Davide, additional, Ubiali, Alessandro, additional, Zangrandi, Adriano, additional, Trubini, Serena, additional, Proietto, Manuela, additional, Gnetti, Letizia, additional, and Tiseo, Marcello, additional

Published
2022
Full Text
View/download PDF

18. Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report

Author

Trudu, Lucia, primary, Guaitoli, Giorgia, additional, Bertolini, Federica, additional, Maur, Michela, additional, Santini, Chiara, additional, Papapietro, Vito Roberto, additional, Talerico, Sabrina, additional, Natalizio, Salvatore, additional, Isca, Chrystel, additional, Dominici, Massimo, additional, and Barbieri, Fausto, additional

Published
2022
Full Text
View/download PDF

20. Additional file 1 of High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Author

Cortellini, Alessio, Giusti, Raffaele, Filetti, Marco, Citarella, Fabrizio, Adamo, Vincenzo, Santini, Daniele, Buti, Sebastiano, Nigro, Olga, Cantini, Luca, Di Maio, Massimo, Aerts, Joachim G. J. V., Bria, Emilio, Bertolini, Federica, Ferrara, Miriam Grazia, Ghidini, Michele, Grossi, Francesco, Guida, Annalisa, Berardi, Rossana, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Antonuzzo, Lorenzo, Gelibter, Alain, Marchetti, Paolo, Chiari, Rita, Macerelli, Marianna, Rastelli, Francesca, Della Gravara, Luigi, Gori, Stefania, Tuzi, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Pecci, Federica, Zoratto, Federica, Ricciardi, Serena, Migliorino, Maria Rita, Passiglia, Francesco, Metro, Giulio, Spinelli, Gian Paolo, Banna, Giuseppe L., Friedlaender, Alex, Addeo, Alfredo, Ficorella, Corrado, Porzio, Giampiero, Tiseo, Marcello, Russano, Marco, Russo, Alessandro, and Pinato, David James

Abstract

Additional file 1. Supplementary materials.

Published
2022
Full Text
View/download PDF

21. Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Author

Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris and Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa and Bergamini, Cristiana Colombo, Elena Caspani, Francesca and Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo

Abstract

Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.

Published
2022

22. Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Author

Economopoulou, Panagiota, primary, Pantazopoulos, Anastasios, additional, Spathis, Aris, additional, Kotsantis, Ioannis, additional, Kyriazoglou, Anastasios, additional, Kavourakis, George, additional, Zakopoulou, Roubini, additional, Chatzidakis, Ioannis, additional, Anastasiou, Maria, additional, Prevezanou, Maria, additional, Resteghini, Carlo, additional, Licitra, Lisa, additional, Bergamini, Cristiana, additional, Colombo, Elena, additional, Caspani, Francesca, additional, Denaro, Nerina, additional, Vecchio, Stefania, additional, Bonomo, Pierluigi, additional, Cossu Rocca, Maria, additional, Bertolini, Federica, additional, Ferrari, Daris, additional, Psyrri, Amanda, additional, and Bossi, Paolo, additional

Published
2021
Full Text
View/download PDF

23. Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

Author

Banna, Giuseppe L., primary, Tiseo, Marcello, additional, Cortinovis, Diego L., additional, Facchinetti, Francesco, additional, Aerts, Joachim G. J. V., additional, Baldessari, Cinzia, additional, Giusti, Raffaele, additional, Bria, Emilio, additional, Grossi, Francesco, additional, Berardi, Rossana, additional, Morabito, Alessandro, additional, Catino, Annamaria, additional, Genova, Carlo, additional, Mazzoni, Francesca, additional, Gelibter, Alain, additional, Rastelli, Francesca, additional, Macerelli, Marianna, additional, Chiari, Rita, additional, Gori, Stefania, additional, Mansueto, Giovanni, additional, Citarella, Fabrizio, additional, Cantini, Luca, additional, Rijavec, Erika, additional, Bertolini, Federica, additional, Cappuzzo, Federico, additional, De Toma, Alessandro, additional, Friedlaender, Alex, additional, Metro, Giulio, additional, Pensieri, Maria Vittoria, additional, Porzio, Giampiero, additional, Ficorella, Corrado, additional, Pinato, David J., additional, Cortellini, Alessio, additional, and Addeo, Alfredo, additional

Published
2021
Full Text
View/download PDF

24. Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy

Author

Baldessari, Cinzia, primary, Pecchi, Annarita, additional, Marcheselli, Raffaella, additional, Guaitoli, Giorgia, additional, Bonacini, Riccardo, additional, Valoriani, Filippo, additional, Torricelli, Pietro, additional, Reverberi, Linda, additional, Menozzi, Renata, additional, Pugliese, Giuseppe, additional, Vitale, Maria Giuseppa, additional, Sabbatini, Roberto, additional, Bertolini, Federica, additional, Barbieri, Fausto, additional, and Dominici, Massimo, additional

Published
2021
Full Text
View/download PDF

25. Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations

Author

Guaitoli, Giorgia, primary, Bertolini, Federica, additional, Bettelli, Stefania, additional, Manfredini, Samantha, additional, Maur, Michela, additional, Trudu, Lucia, additional, Aramini, Beatrice, additional, Masciale, Valentina, additional, Grisendi, Giulia, additional, Dominici, Massimo, additional, and Barbieri, Fausto, additional

Published
2021
Full Text
View/download PDF

26. Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Author

Bruni, Alessio, primary, Scotti, Vieri, additional, Borghetti, Paolo, additional, Vagge, Stefano, additional, Cozzi, Salvatore, additional, D’Angelo, Elisa, additional, Giaj Levra, Niccolò, additional, Fozza, Alessandra, additional, Taraborrelli, Maria, additional, Piperno, Gaia, additional, Vanoni, Valentina, additional, Sepulcri, Matteo, additional, Trovò, Marco, additional, Nardone, Valerio, additional, Lattanzi, Elisabetta, additional, Bou Selman, Said, additional, Bertolini, Federica, additional, Franceschini, Davide, additional, Agustoni, Francesco, additional, Jereczek-Fossa, Barbara Alicja, additional, Magrini, Stefano Maria, additional, Livi, Lorenzo, additional, Lohr, Frank, additional, and Filippi, Andrea Riccardo, additional

Published
2021
Full Text
View/download PDF

28. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Author

Bruni, Alessio, primary, Scotti, Vieri, additional, Borghetti, Paolo, additional, Vagge, Stefano, additional, Cozzi, Salvatore, additional, D’Angelo, Elisa, additional, Giaj Levra, Niccolò, additional, Fozza, Alessandra, additional, Taraborrelli, Maria, additional, Piperno, Gaia, additional, Vanoni, Valentina, additional, Sepulcri, Matteo, additional, Trovò, Marco, additional, Nardone, Valerio, additional, Lattanzi, Elisabetta, additional, Bou Selman, Said, additional, Bertolini, Federica, additional, Franceschini, Davide, additional, Agustoni, Francesco, additional, Jereczek-Fossa, Barbara Alicja, additional, Magrini, Stefano Maria, additional, Livi, Lorenzo, additional, Lohr, Frank, additional, and Filippi, Andrea Riccardo, additional

Published
2021
Full Text
View/download PDF

29. Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study

Author

Celio, Luigi, primary, Cortinovis, Diego, additional, Cogoni, Alessio Aligi, additional, Cavanna, Luigi, additional, Martelli, Olga, additional, Carnio, Simona, additional, Collovà, Elena, additional, Bertolini, Federica, additional, Petrelli, Fausto, additional, Cassano, Alessandra, additional, Chiari, Rita, additional, Zanelli, Francesca, additional, Pisconti, Salvatore, additional, Vittimberga, Isabella, additional, Letizia, Antonietta, additional, Misino, Andrea, additional, Gernone, Angela, additional, Bonizzoni, Erminio, additional, Pilotto, Sara, additional, De Placido, Sabino, additional, and Bria, Emilio, additional

Published
2021
Full Text
View/download PDF

35. Overall survival in patients with lung adenocarcinoma harboring “niche” mutations: an observational study

Author

Aramini, Beatrice, primary, Banchelli, Federico, additional, Bettelli, Stefania, additional, Manfredini, Samantha, additional, D’Amico, Roberto, additional, Masciale, Valentina, additional, Pinelli, Massimo, additional, Moretti, Margherita, additional, Stefani, Alessandro, additional, Bertolini, Federica, additional, Dominici, Massimo, additional, Morandi, Uliano, additional, and Maiorana, Antonino, additional

Published
2020
Full Text
View/download PDF

36. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).

Author

Celio, Luigi, Cortinovis, Diego, Cogoni, Alessio Aligi, Cavanna, Luigi, Martelli, Olga, Carnio, Simona, Collovà, Elena, Bertolini, Federica, Petrelli, Fausto, Cassano, Alessandra, Chiari, Rita, Zanelli, Francesca, Pisconti, Salvatore, Vittimberga, Isabella, Letizia, Antonietta, Misino, Andrea, Gernone, Angela, Bonizzoni, Erminio, Pilotto, Sara, and De Placido, Sabino

Subjects
FOOD consumption, WEIGHT loss, VOMITING, PREVENTIVE medicine, INGESTION, CISPLATIN
Abstract

We demonstrated the non-inferiority of a dexamethasone (DEX)-sparing (single-dose) regimen with NEPA, a netupitant/palonosetron fixed combination, for preventing chemotherapy-induced nausea and vomiting (CINV) caused by cisplatin. This pre-planned exploratory analysis assessed the effect of the DEX-sparing regimen on a patient's food intake. Chemotherapy-naïve patients undergoing cisplatin (≥ 70 mg/m2) were given NEPA and DEX (12 mg) on day 1 and randomized to receive either no further DEX (DEX1), or oral DEX (4 mg BID) on days 2–4 (DEX4). Patient-reported endpoint maintenance of usual daily food intake was assessed during the 5-days post-chemotherapy. The relationship between usual daily food intake and CINV control, pre-chemotherapy self-rated food intake and BMI-adjusted weight loss (WL) were evaluated. One-hundred fifty-two patients (76/group) were assessable. The proportion of patients reporting maintenance of usual daily food intake was similar in both groups: 69.7% (95% CI, 58.6–78.9) for DEX1 vs. 72.4% (95% CI, 61.4–81.2) for DEX4. Only CINV control was significantly associated with maintenance of usual daily food intake (P ≤ 0.001) during the overall phase. The DEX-sparing regimen does not adversely affect patient-reported daily food intake post-chemotherapy. The current analysis adds further insights into antiemetic efficacy of DEX sparing beyond day 1 in the challenging setting of cisplatin. Trial registration: The parent study was registered on ClinicalTrials.gov (NCT04201769). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

Author

Signorelli, Diego, Giannatempo, Patrizia, Grazia, Giulia, Aiello, Marco Maria, Bertolini, Federica, Mirabile, Aurora, Buti, Sebastiano, Vasile, Enrico, Scotti, Vieri, Pisapia, Pasquale, Cona, Maria Silvia, Rolfo, Christian, and Malapelle, Umberto

Subjects
Article Subject
Abstract

Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection.

Published
2019
Full Text
View/download PDF

38. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study (Journal of Neuro-Oncology, (2016), 128, 1, (157-162), 10.1007/s11060-016-2093-1)

Author

Franceschi, Enrico, Depenni, Roberta, Paccapelo, Alexandro, Ermani, Mario, Faedi, Marina, Sturiale, Carmelo, Michiara, Maria, Servadei, Franco, Pavesi, Giacomo, Urbini, Benedetta, Pisanello, Anna, Crisi, Girolamo, Cavallo, Michele A., Dazzi, Claudio, Biasini, Claudia, Bertolini, Federica, Mucciarini, Claudia, Pasini, Giuseppe, Baruzzi, Agostino, Brandes, Alba A., Baruzzi, A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., Brandes, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Cavallo, Marino, Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, Enrico, Biasini, C., Cavanna, L., Guidetti, D., Marcello, Norina, Pisanello, A., Cremonini, A. M., Guiducci, G., de Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, Stefano, Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, Vincenzo, Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Faedi, M., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, Giuseppe, Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, Mario, Pasquini, Elena, Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, Greta, Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, Corrado, Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, Margherita, Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Urbini, B., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., and Nobile, C.

Subjects
Cancer Research, Oncology, Neurology, Neurology (clinical)
Published
2018

40. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report

Author

Luppi Gabriele, Zironi Sandra, Bertolini Federica, Depenni Roberta, Ponti Giovanni, Malavasi Norma, and Conte Pier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response.

Published
2009
Full Text
View/download PDF

41. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study

Author

Marcheselli Luigi, Rashid Ivan, Cirilli Claudia, Valli Riccardo, Bertolini Federica, Rossi Giulio, Mucciarini Claudia, Luppi Gabriele, and Federico Massimo

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Although the diagnostic criteria and pathogenesis of gastrointestinal stromal tumors (GIST) have recently been elucidated, knowledge of the epidemiology of this malignancy is still limited. This study examined the incidence of GIST in the province of Modena, including pathologic features and clinical outcome. Methods Gastrointestinal mesenchymal tumors identified by the Modena Cancer Registry between 1991 and 2004 were analyzed with an immunohistochemical panel that included staining for CD-117 and PDGFRα. Size, mitotic rate, and other pathologic parameters were recorded. Each tumor was categorized into National Institutes of Health risk categories (very low, low, intermediate, and high risk). Results One hundred twenty-four cases were classified as GIST. The age-adjusted incidence rate was 6.6 per million. Seventy-five percent of patients were symptomatic; 34% had a previous or concomitant history of cancer. High-risk features were present in 47% of cases. Seventy-eight percent were submitted to radical surgery. After complete resection, the 5-year disease-free survival rates were 94%, 92%, 100%, and 40% for patients at very low, low, intermediate, and high risk, respectively. In multivariate analysis, high risk was the main predictor of recurrence. Conclusion This population-based study shows that the incidence of GIST in Northern Italy is comparable to that reported in other European countries. Survival was favorable in lower risk categories and in most of the resected cases. In our study, resected patients at very low, low, and intermediate risk had a similar outcome. Our data support the need to consider high-risk patients after complete surgical resection for treatment with the best available approach.

Published
2007
Full Text
View/download PDF

43. Un caso inusuale di interstiziopatia polmonare cistica

Author

Aramini, Beatrice, Stefani, Alessandro, Rossi, Giulio, Pecchi, Annarita, Bertolini, Federica, Falasca, Angelo, Morandi, Uliano, Aramini, Beatrice, STEFANI, Alessandro, ROSSI, Giulio, PECCHI, Annarita, BERTOLINI, Federica, Falasca, Angelo, and MORANDI, Uliano

Subjects
interstiziopatia polmonare, interstiziopatia polmonare, metastasi meningioma, metastasi meningioma
Abstract

Nel marzo 2011, una donna di 27 anni è stata ricoverata per cefalea persistente. La RMN dell’encefalo mostrava una neoformazione parasagittale destra, eterogenea, con aree emorragiche e compressione del tessuto circostante, compatibile con meningioma. Il radiogramma del torace mostrava una interstiziopatia diffusa reticolonodulare e pneumotorace sinistro. La HRCT evidenziava la presenza di lesioni cistiche bilaterali, diffuse prevalentemente ai lobi inferiori e sottopleuriche, micronoduli peribronchiali e centrolobulari e confermava il pneumotorace, completo a sinistra, soltanto apicale a destra. Le cisti, da pochi millimetri a un centimetro, presentavano pareti sottili e tendenza a confluire. La paziente non riferiva sintomatologia respiratoria. La diagnosi radiologica è stata di interstiziopatia polmonare a componente cistica. Gli esami di laboratorio (compresi test-HIV, ANAtest, immunoelettroforesi) e una TC addome-pelvi sono risultati negativi. La paziente è stata sottoposta ad intervento neurochirurgico di rimozione completa della neoplasia cerebrale in craniotomia. La diagnosi istologica è stata di meningioma benigno (grado I). Dopo tre settimane sono state eseguite biopsie polmonari multiple in videotoracoscopia. L'esame istologico ha mostrato una proliferazione di tipo nodulare e cistico di cellule fusate, con rare mitosi, senza necrosi. All’immunoistochimica queste cellule si presentavano diffusamente positive per vimentina, EMA, CD56 e recettori per estrogeni/progesterone, focalmente positive per S100. In considerazione dell’analogo quadro morfologico e immunoistochimico con la neoplasia cerebrale, è stata posta diagnosi di metastasi polmonari da meningioma. Questa diagnosi è stata ulteriormente avvalorata dai test molecolari. La paziente ha iniziato chemioterapia con idrossiurea, interrotta dopo 12 mesi a causa di progressione della malattia polmonare. Da Giugno 29012 è in terapia con everolimus e da allora la malattia rimane stabile. Le metastasi da meningioma sono rare (0,1 % dei meningiomi) e il polmone è l’organo più colpito. Metastatizzano principalmente i meningiomi maligni (grado II-III), eccezionalmente le forme benigne (circa 20 casi riportati in letteratura). Le metastasi polmonari sono descritte in genere come masse o noduli, più spesso isolate, raramente come lesioni multiple o bilaterali. Questo è il primo caso riportato di presentazione con aspetto microcistico. L’aspetto radiologico poneva la diagnosi differenziale con altre forme di interstiziopatia cistica (linfoangioleiomiomatosi, istiocitosi a cellule di Langherans, neurofibromatosi-1, LIP, collagenopatie), per cui è stata obbligatoria la biopsia polmonare. All’esame istologico l’aspetto morfologico non poteva escludere altre proliferazioni a cellule fusate riscontrabili a livello polmonare, (linfoangioleiomiomatosi, meningoteliomatosi) ma le caratteristiche immunoistochimiche nel contesto clinico di un meningioma cerebrale hanno supportato la diagnosi di metastasi. E’ stata decisiva l’analisi molecolare per la diagnosi di certezza.

Published
2014

46. MET DNA Alterations in NSCLC—Letter

Author

Mengoli, Maria Cecilia, primary, Bertolini, Federica, additional, Tiseo, Marcello, additional, Barbieri, Fausto, additional, Fiorentino, Michelangelo, additional, Ardizzoni, Andrea, additional, and Rossi, Giulio, additional

Published
2016
Full Text
View/download PDF

47. Bone metastases- Pharmacological treatment

Author

Guarneri, Valentina, Bertolini, Federica, Cascinu, Stefano, and Ibrahim, T.

Subjects
zoledronic acid, pamidronate, breast cancer, bone metastases, prostate cancer, skeletal related events
Published
2010

48. GLIOMATOSIS CEREBRI: A SINGLE INSTITUTION REPORT

Author

Bertolini, Federica, Depenni, Roberta, Fontana, A., Falasca, A., Meletti, Stefano, Valentini, A., Giacobazzi, P., Cavalleri, F., Zunarelli, E., and Pinna, G. P.

Subjects
gliomatosis, epilepsy
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results